{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:36:28Z","timestamp":1789774588640,"version":"4.0.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to investigate the association between early dynamic trajectories of white blood cell (WBC) count and the risk of differentiation syndrome (DS) during induction therapy with All-trans-retinoic Acid (ATRA) combined with arsenic trioxide (ATO) in pediatric patients with acute promyelocytic leukemia (APL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of pediatric APL patients treated with ATRA and ATO induction therapy between January 2016 and December 2024 is analyzed. Latent growth mixture modeling (LGMM) is employed to identify distinct WBC count trajectories over the first seven days of induction therapy. DS is diagnosed according to Frankel's criteria. Logistic regression analyses are performed to evaluate associations between WBC trajectory classes and the occurrence of DS, treatment-related complications, and transfusion requirements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 93 patients are included, with an overall incidence of DS of 40.9% during induction therapy. Four distinct WBC trajectory classes are identified: Class 1 (high-level increasing group), Class 2 (high-level decreasing group), Class 3 (persistently low-level group), and Class 4 (low-level increasing group). After adjustment for potential confounders, patients in Class 1 (OR: 11.37, 95% CI: 1.17\u2013124.71) and Class 4 (OR: 8.34, 95% CI: 1.94\u201335.92) remain at significantly increased risk of DS compared to those in Class 3, while no significant difference in DS risk is observed between Class 2 and Class 3. Furthermore, patients in Class 1 require more frequent transfusion support, including red blood cells, platelets, and plasma (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) during induction therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The trajectory of WBC count during ATRA and ATO induction therapy may serve as an indicator for predicting the risk of DS in pediatric APL patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2025.1742083","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:52:35Z","timestamp":1767768755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of white blood cell count trajectories on the risk of differentiation syndrome during induction therapy with all-trans-retinoic acid and arsenic trioxide in pediatric acute promyelocytic leukemia"],"prefix":"10.3389","volume":"13","author":[{"given":"Houxin","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/bjh.19759","article-title":"Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications","volume":"205","author":"Cicconi","year":"2024","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1056\/NEJMicm2314162","article-title":"Acute promyelocytic leukemia","volume":"390","author":"Winkler","year":"2024","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E370","DOI":"10.1002\/ajh.25252","article-title":"Complications and early mortality in patients with acute promyelocytic leukemia treated in California","volume":"93","author":"Ho","year":"2018","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3324\/haematol.2021.278851","article-title":"Early mortality and survival improvements for adolescents and young adults with acute promyelocytic leukemia in California: an updated analysis","volume":"107","author":"Abrah\u00e3o","year":"2022","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/cancers16061160","article-title":"Acute promyelocytic leukemia: review of complications related to all-trans retinoic acid and arsenic trioxide therapy","volume":"16","author":"Ghiaur","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/ijms22020642","article-title":"Acute promyelocytic leukemia in children: a model of precision medicine and chemotherapy-free therapy","volume":"22","author":"Gurnari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br J Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.1016\/S0049-3848(14)50019-9","article-title":"Thrombo-hemorrhagic deaths in acute promyelocytic leukemia","volume":"133","author":"Breccia","year":"2014","journal-title":"Thromb Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1007\/s00277-024-05776-y","article-title":"Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide","volume":"103","author":"Gao","year":"2024","journal-title":"Ann Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/asheducation-2006.1.156","article-title":"The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment","volume":"2006","author":"Lo-Coco","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13054-021-03586-6","article-title":"Temporal patterns of organ dysfunction after severe trauma","volume":"25","author":"Eriksson","year":"2021","journal-title":"Crit Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B17","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41375-019-0589-3","article-title":"Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial","volume":"34","author":"Cicconi","year":"2020","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3892\/mco.2021.2274","article-title":"Dynamic changes and multiplication rate of white blood cell count may direct the timing of cytoreduction chemotherapy during induction treatment in newly diagnosed acute promyelocytic leukemia with low-intermediate risk","volume":"14","author":"Wen","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"B19","first-page":"421","article-title":"Relationship between cytokines and leukocytosis in patients with APL induced by all-trans retinoic acid or arsenic trioxide","volume":"3","author":"Bi","year":"2006","journal-title":"Cell Mol Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1098\/rstb.2007.2026","article-title":"Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy","volume":"362","author":"Zhou","year":"2007","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1159\/000492646","article-title":"Autophagy and ubiquitin-mediated proteolytic degradation of PML\/rar\u03b1 fusion protein in matrine-induced differentiation sensitivity recovery of ATRA-resistant APL (NB4-LR1) cells: in vitro and in vivo studies","volume":"48","author":"Wu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B22","doi-asserted-by":"publisher","first-page":"772408","DOI":"10.3389\/fimmu.2021.772408","article-title":"Inflammatory cytokines shape an altered immune response during myeloid malignancies","volume":"12","author":"Camacho","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104802","DOI":"10.1016\/j.amsu.2022.104802","article-title":"Novel insights on the role of VCAM-1 and ICAM-1: potential biomarkers for cardiovascular diseases","volume":"84","author":"Kaur","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1080\/03639045.2020.1821050","article-title":"Development of arsenic trioxide sustained-release pellets for reducing toxicity and improving compliance","volume":"46","author":"Liu","year":"2020","journal-title":"Drug Dev Ind Pharm"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1742083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:52:36Z","timestamp":1767768756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1742083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":24,"alternative-id":["10.3389\/fped.2025.1742083"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1742083","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1742083"}}